Teva Agilect Labeling Not Yet Negotiated With FDA; User Fee Date Is Aug. 4
This article was originally published in The Pink Sheet Daily
Executive Summary
Labeling for Agilect (rasagiline) has not yet been negotiated with FDA despite the Parkinson's disease agent's August 4 user fee date, Teva says
You may also be interested in...
FDA Extends Agilect User Fee Deadline Due To “Technical Error”
FDA is extending the user fee deadline for Teva's Parkinson's disease agent Agilect (rasagiline) by three months following the firm's submission of additional data to clarify a "technical error.
Italy Leads European Push Into Conditional Reimbursement
Italy claims to have pushed farther into managed entry agreements than other European countries with strong clawback provisions on new drugs – particularly cancer drugs – if they don't work as well as their manufacturers claim. The financial clawbacks are supported by extensive outcome data collection across the country's twenty regions.
Changes To The NHS: How Can Pharma Best Position Itself?
The U.K.’s Health and Social Care Bill was introduced into Parliament on Jan. 19, offering a new commercial landscape best navigated by pharma through bolstered relationships with general practitioners.